# Data Sheet (Cat.No.T6918)

TargetMol

## Olmutinib

### Chemical Properties



CAS No. : 1353550-13-6

Formula: C26H26N6O2S

Molecular Weight: 486.59

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild-type form. |
| Targets(IC50) | EGFR,BTK |
| In vitro | HM61713 causes potent inhibition in cell lines H1975 (L858R and T790M) and HCC827 (exon 19 deletion). It has a low potency for NSCLC cell line H358 harboring wild-type EGFR (GI50 of 2225 nM)[1]. |
| In vivo | HM61713 has a half-life of over 24 h for EGFR inhibition. In the in vivo studies of xenograft models with grafts of H1975 and HCC827, HM61713 is active against the tumors without showing any side effects[1]. |

### Solubility Information

| | |
|---|---|
| Solubility | Ethanol: 22 mg/mL (45.21 mM),Sonication is recommended.<br>DMSO: 250 mg/mL (513.78 mM),Sonication is recommended.<br>H2O: < 1 mg/mL (insoluble or slightly soluble),<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+90% Saline: < 10 mg/mL (20.55 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (20.55 mM),Solution.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.0551 mL | 10.2756 mL | 20.5512 mL |
| 5 mM | 0.411 mL | 2.0551 mL | 4.1102 mL |
| 10 mM | 0.2055 mL | 1.0276 mL | 2.0551 mL |
| 50 mM | 0.0411 mL | 0.2055 mL | 0.411 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wang S, et al. J Hematol Oncol. 2016, 9: 34.